45results about How to "Inhibit gastric acid secretion" patented technology

The present invention relates to novel human glucagon-like peptide-2 (GLP-2) peptides and human glucagon-like peptide-2 derivatives which have a protracted profile of action as well as polynucleotide constructs encoding such peptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

The present invention is related to novel oral compositions comprising an irreversible gastric H⁺/K⁺-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.

The present invention is related to novel oral compositions comprising an irreversible gastric H⁺/K⁺-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor, pentagastrin (PG) or a PG analogue as an activator of parietal cells in the gastric lumen. In a preferred embodiment, the composition further comprises at least one agent that preserves the availability of PG in the gastric fluids, thus enabling PG to act locally in the stomach. Unexpectedly, the compositions of the present invention exhibit anti-acid activity locally in the stomach that is meal-independent, exhibit fast onset and prolonged inhibition of acid secretion.

The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I)

wherein R¹ is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle optionally has substituent(s), R² is an optionally substituted C_6-14 aryl group, an optionally substituted thienyl group or an optionally substituted pyridyl group, R³ and R⁴ are each a hydrogen atom, or one of R³ and R⁴ is a hydrogen atom and the other is an optionally substituted lower alkyl group, an acyl group, a halogen atom, a cyano group or a nitro group, and R⁵ is an alkyl group or a salt thereof.

The invention provides magnesium S-omeprazolato compounds according to formula (I):

[Mg(solv_a)_x(solv_b)_y][Mg(S-omeprazolato)₃]₂.(solv_c)_z  (I),

pharmaceutical compositions and processes of making the same. In formula (I), solv_a, solv_b, and solv_c represent solvent molecules where x and y are independently selected from integers 0 to 6, the sum of which is 4 or 6, while z is a positive rational number from 0 to 6. The compounds are useful for the treatment of gastric acid related conditions and the inhibition of gastric acid secretion.

The invention relates to solid state forms of enantiopure ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfnyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a solid form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders such as those discussed above.

The present invention provides a compound having a superior acid secretion inhibitory action, an antiulcer activity and the like.

A proton pump inhibitor containing a compound represented by the formula (I)

wherein ring A is a saturated or unsaturated 5- or 6-membered ring group optionally having, as a ring-constituting atom besides carbon atom, 1 to 4 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, ring-constituting atoms X₁ and X₂ are each a carbon atom or a nitrogen atom, a ring-constituting atom X₃ is a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom, R¹ is an optionally substituted aryl group or an optionally substituted heteroaryl group, R² is an optionally substituted alkyl group, an optionally substituted aryl group or an optionally substituted heteroaryl group, R³ is an aminomethyl group optionally substituted by 1 or 2 lower alkyl groups, which is a substituent on a ring-constituting atom other than X₁, X₂ and X₃, and ring A optionally further has substituent(s) selected from a lower alkyl group, a halogen atom, a cyano group and an oxo group, or a salt thereof or a prodrug thereof.

The invention belongs to the technical field of medicines and particularly relates to a novel pyridine derivative shown, stereoisomers of the pyridine derivative, pharmaceutically acceptable salts of the pyridine derivative, solvates of the pyridine derivate in the general formula (I) and intermediates shown in the general formulas (I') and (II), wherein R1, R2, R3, R4, R5 and n are as defined in a specification; the invention also relates to preparation methods for the compounds, a medicine combination containing the medicine compounds, and the application of the compounds in medicines for preventing and/or treating peptic ulcers, ulcer bleeding and diseases related to gastric acids.

The present invention discloses one kind of Chinese medicine preparation for clearing away heat of throat. The Chinese medicine preparation is prepared with holly root 1-5 weight portions, isatis root 1-5 weight portions, elephantopus 1-5 weight portions, and licorice 1-5 weight portions. The Chinese medicine preparation has high curative effect on influenza, upper respiratory tract infection, tonsillitis, etc. and possesses certain bacteriostasis and killing effect on staphylococcus aureus, type-A hemolytic streptococcus, type-B hemolytic streptococcus, etc.

The invention belongs to the pharmaceutical technical field and specifically relates to hydrosulphonyl benzoglioxaline derivatives which are shown in general formula (I) and contain dioxo heptane pyridine, isomers and pharmaceutically acceptable salts thereof, wherein, R, R and R are defined as in the specification. The invention also relates to preparation methods of the compounds, drug compositions containing the compounds and the application of the compounds in preparing drugs for preventing and/or treating digestive ulcer.

The invention belongs to the pharmaceutical technical field and specifically relates to benzoglioxaline derivatives which are shown in general formula (I) and contain naphthyridine tetrahydrochysene isoxazole substituted by alcoxyl ethide, pharmaceutically acceptable salts and isomers thereof, wherein, R, R and R are defined as in the specification. The invention also relates to preparation methods of the compounds, drug compositions containing the compounds and the application of the compounds in preparing drugs for preventing and/or treating digestive ulcer.

The present invention relates to a pharmaceutical composition comprising pancreatin, which has a coating that contains a least one lipase. Preferably the at least one lipase is burlulipase. It also relates to a medicinal product comprising such a pharmaceutical composition. A method of producing such a pharmaceutical composition also forms part of the present invention.

The invention belongs to the pharmaceutical technical field and specifically relates to hydrosulphonyl benzoglioxaline derivatives which are shown in general formula (I) and contain dihydrofuran pyridine, pharmaceutically acceptable salts and isomers thereof, wherein, R, R, R and R are defined as in the specification. The invention also relates to preparation methods of the compounds, drug compositions containing the compounds and the application of the compounds in preparing drugs for preventing and/or treating digestive ulcer.

The invention relates to crystalline forms of various solvates of ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising crystalline ilaprazole hydrate according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.

The invention belongs to the technical field of medicine, and in particular relates to compounds which are shown in a general formula (I) and contain imidazopyridine, pharmaceutically acceptable salts of the same and isomers of the same, wherein R, R, R, and X are defined in a specification. The invention also relates to a method for preparing the compounds, a pharmaceutical composition containing the compounds, and application of the compounds to preparation of medicines for preventing and/or treating peptic ulcer.

The invention belongs to the technical field of medicine, and in particular relates to compounds of imidazopyridine which are shown in a general formula (I) and contain aminooxy substituted pyridine, pharmaceutically acceptable salts of the same and isomers of the same, wherein R, R, R and R are defined in a specification. The invention also relates to a method for preparing the compounds, a pharmaceutical composition containing the compounds, and application of the compounds to preparation of medicines for preventing and/or treating peptic ulcer.